As radiopharmaceuticals enter a new phase, industry leaders must rethink external services and internal capabilities to master the complexities of delivering advanced therapies.
Endocyte entered its targeted radioligand therapy, Lu-PSMA-617, into a Phase III study in June following Phase II data showing more than 60 percent response rate.
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.